Phaseline

Companies › BioLineRx

BioLineRx: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Motixafortide (BL-8040)
C-X-C chemokine receptor type 4 antagonist
CXCR4Phase 3Multiple MyelomaSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03246529Motixafortide (BL-8040)Phase 3Multiple MyelomaOncologySep 2029

From the company's SEC filings

Cash and short-term investments of $21m on 2025-12-31; operating cash outflow about $8m a year; runway about 31 months at that burn, to Jul 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway

Private offerings reported to the SEC (Form D)

Targets

CXCR4 (1)

Companies with the same targets

Guangzhou Gloria Biosciences X4 Pharmaceuticals

Companies built like this

Celcuity Black Diamond Therapeutics Kyntra Bio Verity Pharmaceuticals SecuraBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.